A Schlesinger-Raab1, G Schubert-Fritschle2, R Hein3, W Stolz4, M Volkenandt5, D Hölzel2, J Engel2. 1. Munich Cancer Registry of the Munich Cancer Centre, Department of Medical Informatics, Biometry und Epidemiology, Ludwig-Maximilians-University. Electronic address: schlesi@ibe.med.uni-muenchen.de. 2. Munich Cancer Registry of the Munich Cancer Centre, Department of Medical Informatics, Biometry und Epidemiology, Ludwig-Maximilians-University. 3. Clinic and Policlinic for Dermatology and Allergology "am Biederstein", Technical University Munich. 4. Clinic for Dermatology, Allergology and Environmental Medicine, Hospital Munich-Schwabing. 5. Clinic and Policlinic for Dermatology and Allergology, Ludwig-Maximilians-University, Munich, Germany.
Abstract
BACKGROUND: The incidence of melanoma is still increasing in fair-skinned populations. At least 80% of patients have localised disease and expect a 5-year relative survival of >90%. PATIENTS AND METHODS: In 2003-2004, disease-free patients with localised melanoma were recruited from the Munich Cancer Registry to answer quality-of-life (QoL) questionnaires 2 years after treatment. RESULTS: A response rate of 72% was achieved from a total of 1085 distributed questionnaires. Hundred and seventeen questionnaires had to be excluded because of updated information about secondary tumour and progression events. Thus, questionnaires from 664 patients were evaluated. QoL scores in melanoma patients were essentially similar to those of a general population. Differences were detected between women and men concerning emotional and sexual functioning. Age and number of comorbidities were the strongest factors influencing most all aspects of QoL. Fifty percent of patients referred to deficits in communication with their doctors. CONCLUSIONS: Patients who overcome melanoma do not necessarily have a reduced QoL. Strategies used by these melanoma patients resulted in similar levels of coping as previous studies in comparable general populations. Nevertheless, doctor-patient communication was correlated with emotional and social functioning and should be emphasised in treatment and care of melanoma patients.
BACKGROUND: The incidence of melanoma is still increasing in fair-skinned populations. At least 80% of patients have localised disease and expect a 5-year relative survival of >90%. PATIENTS AND METHODS: In 2003-2004, disease-free patients with localised melanoma were recruited from the Munich Cancer Registry to answer quality-of-life (QoL) questionnaires 2 years after treatment. RESULTS: A response rate of 72% was achieved from a total of 1085 distributed questionnaires. Hundred and seventeen questionnaires had to be excluded because of updated information about secondary tumour and progression events. Thus, questionnaires from 664 patients were evaluated. QoL scores in melanomapatients were essentially similar to those of a general population. Differences were detected between women and men concerning emotional and sexual functioning. Age and number of comorbidities were the strongest factors influencing most all aspects of QoL. Fifty percent of patients referred to deficits in communication with their doctors. CONCLUSIONS:Patients who overcome melanoma do not necessarily have a reduced QoL. Strategies used by these melanomapatients resulted in similar levels of coping as previous studies in comparable general populations. Nevertheless, doctor-patient communication was correlated with emotional and social functioning and should be emphasised in treatment and care of melanomapatients.
Authors: Susan A Oliveria; Elyse Shuk; Jennifer L Hay; Maureen Heneghan; Jacqueline M Goulart; Katherine Panageas; Alan C Geller; Allan C Halpern Journal: Psychooncology Date: 2011-10-06 Impact factor: 3.894
Authors: Oxana Palesh; Arianna Aldridge-Gerry; Kelly Bugos; David Pickham; Jie Jane Chen; Ralph Greco; Susan M Swetter Journal: Support Care Cancer Date: 2014-05-31 Impact factor: 3.603
Authors: Zoe Stamataki; L Brunton; P Lorigan; A C Green; J Newton-Bishop; A Molassiotis Journal: Support Care Cancer Date: 2014-09-05 Impact factor: 3.603
Authors: Anne L Ryan; Charlotte Burns; Aditya K Gupta; Ruvishani Samarasekera; David S Ziegler; Maria L Kirby; Frank Alvaro; Peter Downie; Stephen J Laughton; Siobhan Cross; Timothy Hassall; Geoff B McCowage; Jordan R Hansford; Rishi S Kotecha; Nicholas G Gottardo Journal: Front Oncol Date: 2021-04-29 Impact factor: 6.244
Authors: Rachel I Vogel; Broderick Yoerg; Patricia I Jewett; Nathan Rubin; Megan Olson; Ashley E Stenzel; Rehana L Ahmed; DeAnn Lazovich Journal: Support Care Cancer Date: 2021-02-12 Impact factor: 3.359
Authors: Evan S Weitman; Matthew Perez; John F Thompson; Robert H I Andtbacka; Jo Dalton; Mona L Martin; Talia Miller; Chad Gwaltney; David Sarson; Eric Wachter; Jonathan S Zager Journal: Melanoma Res Date: 2018-04 Impact factor: 3.599
Authors: Anne Rogiers; Annelies Boekhout; Julia K Schwarze; Gil Awada; Christian U Blank; Bart Neyns Journal: J Oncol Date: 2019-04-28 Impact factor: 4.375